NeoClone is a leading brand that specializes in the production and development of high-quality antibodies. Established in 1999 by three scientists from the University of Wisconsin, NeoClone was driven by a mission to improve antibody discovery and development for the benefit of human health. They have since become a trusted name in the field, with a global customer base of over 1000 in more than 30 countries.

At NeoClone, their expertise lies in the creation of custom antibodies using their innovative NeoAb process. This process ensures the delivery of antibodies of the highest quality, making them ideal for use in diagnostics and as reagents for research purposes. In addition to their custom antibody services, NeoClone also offers bioinformatics support, custom hybridoma development, and antibody phage display technology.

To stay at the forefront of antibody development, NeoClone has expanded its capabilities to include camelid (VHH) antibody production, catering to the rapidly growing therapeutics market. This ensures that they can meet the diverse and specific needs of their customers. With a strong commitment to excellence and a passion for advancing antibody science, NeoClone continues to enhance its antibody development abilities to provide cutting-edge solutions for the life science industry.

To learn more about NeoClone and their services, you can reach out to NeoClone's CEO, Deven McGlenn